NCT06993844 2026-03-17Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsEnsem TherapeuticsPhase 1/2 Recruiting233 enrolled
NCT07038369 2026-03-17A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K MutationsAtavistik Bio, IncPhase 1 Active not recruiting134 enrolled
NCT04784715 2026-02-20Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)AstraZenecaPhase 3 Active not recruiting1,157 enrolled 3 FDA
NCT06886659 2025-07-22A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)Incepta Pharmaceuticals LtdPhase 1 Completed80 enrolled